Akero Therapeutics (AKRO) Slides After Failed Trial, Hit
SAN FRANCISCO, May 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Akero Therapeutics, Inc. (NASDAQ: AKRO) investors who suffered substantial losses to...
Reed Kathrein Hagens Berman Akero Therapeutics Inc Akero Therapeutics Plaintiff Deadline Securities Fraud Class Action
Source: globenewswire.com